Treatment of Lupus Nephritis

Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus

“…This is consistent with past investigations of serologically active clinically quiescent patients, revealing no difference in nephrologic involvement compared to a large group of SLE controls (n = 868) 18 , and commensurate with widely cited renal SLE prevalence 25 . This is consistent with past investigations of serologically active clinically quiescent patients, revealing no difference in nephrologic involvement compared to a large group of SLE controls (n = 868) 18 , and commensurate with widely cited renal SLE prevalence 25 .…”

“…This is consistent with past investigations of serologically active clinically quiescent patients, revealing no difference in nephrologic involvement compared to a large group of SLE controls (n = 868) 18 , and commensurate with widely cited renal SLE prevalence 25 . While these findings may be suggestive of differing organ involvement in those patients with SLE achieving prolonged remission, they should be borne out in a larger sample of remitted patients, ideally over multiple centers, internationally, especially given the notoriously variable prevalence reported in these organ systems 25,26,27 . We observed a lower prevalence of central nervous system manifestations in cases than controls at the start of the remission period.…”

Risk Assessment of Cyclophosphamide and Mycophenolate Mofetil after Induction Treatment of Lupus Nephritis: A Single Center Quasi-Experimental Study

“…Renal involvement in SLE is an important cause of morbidity and mortality. [4][5] During the treatment, nearly all patients report one or more Adverse Events (AEs), and these AEs shape doctors' preferences, especially when two drugs are considered to be equivalent. Serious AEs (SAEs) refer to events that result in death, are life threatening, require inpatient hospitalizationor cause prolongation of existing hospitalization result in persistent or significant disability/ incapacity, lead to a congenital anomaly/ birth defect or that require intervention to prevent permanent impairment or damage.These effects can directly demonstrate the safety of available drugs in different aspects, eliminating the interference of more On different literature reviews show that MMF showed equivalency to CYP for induction treatment of lupus nephritis.…”